Myelin loss in C9orf72 hexanucleotide expansion carriers
Myelin loss in C9orf72 hexanucleotide expansion carriers The expansion of the intronic GGGGCC repeat (G4C2) in the C9orf72 gene is the most common genetic cause of Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS) and in the continuum of...
The link between Alzheimer’s disease and Down syndrome
The link between Alzheimer’s disease and Down syndrome People with Down syndrome are genetically predisposed to developing Alzheimer´s disease. The strong association between Alzheimer disease and Down syndrome has a genetic basis through a gene-dose effect of the...
World Down Syndrome Day
Today, March 21, the Memory Unit and the Alzheimer Down Unit celebrate World Down Syndrome Day. Because diversity enriches, we work to achieve an inclusive and equal world for...
Concordance between amyloid markers in CSF
Amyloid peptides and tau markers in CSF Cerebrospinal fluid (CSF) biomarkers of Alzheimer’s disease (AD), such as β-amyloid 1-42 (Aβ1-42), total tau (tTau) and pTau181, have improved the management of patients with cognitive impairment. Although Aβ1-42 is...
Victor Montal defends his Doctoral Thesis
Víctor Montal Blancafort has presented today his Doctoral Thesis entitled “Complex neuroimaging changes in metabolite, cortical structures and regional vulnerabilities in the Alzheimer disease continuum“. The thesis, directed by Dr. Juan Fortea and...
Jordi Pegueroles defends his Doctoral Thesis
In January 18th 2022, Jordi Pegueroles Monllau presented his doctoral thesis entitled “The role of biomarkers in the current classification systems for Alzheimer’s Disease“. The thesis has been supervised by Dr. Juan Fortea and tutored by Dr....
GFAP in blood helps predict the evolution of frontotemporal dementia
GFAP and frontotemporal dementia Frontotemporal dementia is a heterogeneous entity with variable clinical manifestations. As a consequence, it can be confused with psychiatric diseases or other neurodegenerative diseases such as Alzheimer’s disease. Despite the...
New plasma biomarker to detect Alzheimer’s disease in Down syndrome individuals
Plasma biomarkers Scientists worldwide are immersed in the race for accurate, non-invasive and accessible biomarkers to detect and diagnose Alzheimer’s Disease. To date, major scientific advances allowed the identification of several biomarkers in cerebrospinal fluid...